Hum. Reprod. Advance Access published online on April 2, 2008
Human Reproduction, doi:10.1093/humrep/den108
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Relevance of anti-Mullerian hormone measurement in a routine IVF program
1 Center for Family Planning, Gynecological Endocrinology and Reproductive Medicine, Rheydter Strasse 143, 41515 Grevenbroich, Germany 2 Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany 3 Department of Obstetrics and Gynecology, University of Muenster, Muenster, Germany 4 Biometric Research Group, Clinic for Thoracic and Cardiovascular Surgery, Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany
5 Correspondence address. Tel: +49-2181-491513; Fax: +49 2181-491534; E-mail: dr.christian.gnoth{at}rmz-nrw.de
BACKGROUND: Diminished ovarian reserve has become a major cause of infertility. Anti-Mullerian hormone (AMH) seems to be a promising candidate to assess ovarian reserve and predict the response to controlled ovarian hyperstimulation (COH). This prospective study was conducted to evaluate the relevance of AMH in a routine IVF program.
METHODS: Three hundred and sixteen patients were prospectively enrolled to enter their first IVF/ICSI-cycle. Age, FSH-, inhibin B- and AMH-levels and their predictive values for ovarian response and clinical pregnancy rate were compared by discriminant analyses.
RESULTS: A total of 132 oocyte retrievals were performed. A calculated cut-off level 
1.26 ng/ml AMH alone detected poor responders (4 oocytes) with a sensitivity of 97%, and there was a 98% correct prediction of normal response in COH if levels were above this threshold. With levels <0.5 ng/ml, a correct prediction of very poor response (2 oocytes) was possible in 88% of cases. Levels of AMH 
0.5 ng/ml were not significantly correlated with clinical pregnancy rates.
CONCLUSIONS: AMH is a predictor of ovarian response and suitable for screening. Levels 1.26 ng/ml are highly predictive of reduced ovarian reserve and should be confirmed by a second line antral follicle count. Measurement of AMH supports clinical decisions, but alone it is not a suitable predictor of IVF success.
Submitted on August 21, 2007; resubmitted on March 3, 2008; accepted on March 12, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. La Marca, G. Sighinolfi, D. Radi, C. Argento, E. Baraldi, A. C. Artenisio, G. Stabile, and A. Volpe Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Hum. Reprod. Update, September 30, 2009; (2009) dmp036v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. La Marca, F.J. Broekmans, A. Volpe, B.C. Fauser, N.S. Macklon, and on behalf of the ESHRE Special Interest Group for Anti-Mullerian hormone (AMH): what do we still need to know? Hum. Reprod., September 1, 2009; 24(9): 2264 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hudecova, J. Holte, M. Olovsson, and I. Sundstrom Poromaa Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve Hum. Reprod., May 1, 2009; 24(5): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lie Fong, J.S.E. Laven, F.G.A.J. Hakvoort-Cammel, I. Schipper, J.A. Visser, A.P.N. Themmen, F.H. de Jong, and M.M. van den Heuvel-Eibrink Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone Hum. Reprod., April 1, 2009; 24(4): 982 - 990. [Abstract] [Full Text] [PDF]
|
|